Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review.
Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro M, Guerrero JJ, Gellaco MML, Lippi G, Henry BM, Fernández-de-Las-Peñas C. · 2022
Read Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. by Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro M, Guerrero JJ, Gellaco MML, Lippi G, Henry BM, Fernández-de-Las-Peñas C. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9417563.txt.
Introduction
Notarte and co-authors set out a systematic review of COVID-19 vaccination and long-COVID. Vaccines cut the risk of severe illness. Whether they change the odds of long-COVID, or ease it once present, was unclear. The team searched major databases and preprint servers to June 20, 2022.
From 2,584 finds, 17 studies entered the review. Six asked if vaccination before infection lowered long-COVID risk. The answer leaned yes, with two doses stronger than one. Eleven studies tracked symptoms in people who already had long-COVID. Seven found symptoms eased after at least one dose. Four found no change or a worsening. The authors rate the proof as low level. They call the effect on existing symptoms still unsettled.
Catalog record
| CREATOR | Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro M, Guerrero JJ, Gellaco MML, Lippi G, Henry BM, Fernández-de-Las-Peñas C. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review By Kin Israel Notarte, Jesus Alfonso Catahay, Jacqueline Veronica Velasco, Adriel Pastrana, Abbygail Therese Ver, Flos Carmeli Pangilinan, Princess Juneire Peligro, Michael Casimiro, Jonathan Jaime Guerrero, Ma Margarita Leticia Gellaco, Giuseppe Lippi, Brandon Michael Henry Published in: eClinicalMedicine DOI: 10.1016/j.eclinm.2022.101624 ABSTRACT Summary Background Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. Methods MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. Findings From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (n=14/17) studies was high. Six studies (n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. Interpretation Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. Funding The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. Keywords: Post-COVID syndrome, Long-COVID symptoms, Vaccine, SARS-CoV-2 Research in contextEvidence before this studyWe searched PubMed and Web of Science databases for studies published until April 1, 2022, using keywords “long-COVID”, OR “post-COVID” AND “vaccine” OR “vaccination”. We identified different studies analyzing the impact of COVID-19 vaccination in long COVID symptoms, but no systematic review was available in the literature.Added value of this studyThis first systematic review evaluating evidence to date about the impact of vaccines on long COVID supports that vaccination before SARS-CoV-2 infection is able to reduce the risk of developing long-COVID. The impact of vaccination in people with long-COVID symptomatology is controversial, with data showing changes in symptoms and others did not.Implications of all the available evidenceCurrent results support that COVID-19 vaccines can be used as preventive strategy for decreasing the risk of long-COVID, but data about its effects on people with current long-COVID needs further research. Questions about the impact on hospitalised/non-hospitalised, males/females and the impact of vaccine boosters is clearly needed.Alt-text: Unlabelled box INTRODUCTION COVID-19 caused by SARS-CoV-2 is the deadliest communicable healthcare outbreak of the 21st century. COVID-19 vaccines have significantly reduced the risk of developing the severe or critical forms of disease, as well as mortality brought by COVID-19.1 Nonetheless, vaccines seem unable to fully reduce the spread of SARS-CoV-2 variants of concerns (VOCs).2 Following the COVID-19 outbreak, leading to hundreds of millions of acute cases and six million deaths, healthcare professionals are in front of another crisis brought about by development and/or persistence of symptoms after the acute phase of SARS-CoV-2 infection (typically after 3 months), a condition conventionally called long-COVID3 or post-COVID.4 More than 100 symptoms can appear after a SARS-CoV-2 acute infection, affecting multiple systems, e.g., cardiovascular, respiratory, musculoskeletal, or neurological.5 Several meta-analyses observed that almost 50% of COVID-19 survivors had a lingering plethora of symptoms lasting for weeks or months6, 7, 8 but also one year9,10 after SARS-CoV-2 infection. As of August 2022, more than 12.4 billion COVID-19 vaccine doses have been administered globally.11 Although vaccination decreases the risk of severe COVID-19, it is unclear whether vaccination before or after an acute infection improves or reduces the prevalence of long-COVID symptoms. In fact, vaccinated people can still be infected and suffer from asymptomatic, mild or moderate COVID-19, especially when the infection is sustained by VOCs (namely Omicron). Since long-COVID can arise even after a mild or asymptomatic SARS-CoV-2 infection,12 it is in question what real impact vaccines will have on long-COVID.13, 14, 15, 16 This review is the first to date to systematically investigate the impact of COVID-19 vaccination on long-COVID symptoms. Therefore, the research question of this review was: “what is the impact of COVID-19 vaccines on the risk of developing long-COVID or on existing long-COVID in COVID-19 survivors? METHODS This systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement,17 and was prospectively registered in the Open Science Framework (OSF) database (https://osf.io/34djr). No ethical committed is needed for a systematic review. Search strategy and selection criteria Electronic literature searches were conducted by two different authors on the following databases: MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as on preprint servers medRxiv and bioRxiv, for studies published until June 20, 2022. Database search strategies were conducted with assistance of an experienced health science librarian. We also screened the reference list of identified papers for capturing black literature. Searches were limited to human studies and English language citations by using the following combinations of terms: “long-COVID”, “long-COVID symptoms”, “long hauler”, “post-COVID-19” OR “post-acute COVID-19 syndrome” OR “post-acute COVID-19 symptoms” OR “COVID-19 sequelae” AND “vaccine” OR “vaccination” OR “COVID-19 vaccines” OR “SARS-CoV-2 vaccine”. The search strategy combined these terms using Boolean operators for the main databases is detailed in Supplementary Table. The inclusion and exclusion criteria were formulated using the Population, Intervention, Comparison and Outcome (PICO) principle: - Population: Adults (>18 years) infected by SARS-CoV-2 and diagnosed with real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. Individuals could have been hospitalised or not by SARS-CoV-2 acute infection. - Intervention: Any type of COVID-19 vaccine. We included the following types of COVID-19 vaccines: BNT162b2 (“Pfizer/BioNTech”), AZD1222 (“Oxford-AstraZeneca”), mRNA-1273 (“Moderna”), and Ad26.COV2.S (“Janssen”). Vaccine doses can be administered before or after SARS-CoV-2 acute infection. - Comparison: Individuals not receiving any COVID-19 vaccine. - Outcome: Collection of multiple symptoms (post-COVID-19 or long-COVID) developed after a SARS-CoV-2 acute infection (https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid/) by personal, telephone, or electronic interviews. We included any type of symptom appearing after the infection e.g., physical (fatigue, pain), cognitive (brain fog, memory loss), respiratory (dyspnea, palpitations, cough), gastrointestinal (diarrhoea, stomachache, vomiting) or mental problems (depression, anxiety, sleep disturbances). Due to the different definitions of long-COVID, no specific follow-up period for the presence of symptoms after the acute infection was determined. Studies monitoring solely changes in immunologic or serologic biomarkers without assessment of post-COVID symptoms were excluded. This review included observational cohort, cross-sectional, and case-control studies where samples of COVID-19 survivors, either hospitalised or non-hospitalised, were followed for presence of symptoms appearing after a SARS-CoV-2 acute infection before or after COVID-19 vaccination. Editorials, opinion, and correspondence articles were excluded. Two authors reviewed the title and abstract of those publications identified in the